vTv Therapeutics (FRA:5VT0) Moat Score: 2/10 (As of Jul. 01, 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €31.20
GF Value €6,488.10
! 1 Warning Sign
View Full Analysis

What is vTv Therapeutics Moat Score?

vTv Therapeutics FRA:5VT0 +3.31% 35 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,488.10. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, vTv Therapeutics ranks better than 58.07% on this metric.

vTv Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

vTv Therapeutics has No Moat: vTv Therapeutics Inc lacks significant market leadership and has limited intellectual property that provides a competitive edge. The company does not exhibit strong brand strength or customer loyalty, and there are no significant regulatory barriers or cost advantages that would suggest a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes vTv Therapeutics might have No Moat - Very weak/transient advantages.

vTv Therapeutics  (FRA:5VT0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

vTv Therapeutics Moat Score Related Terms

FRA:5VT0 vs SMNR, CNTB, ENLV: Moat Score Comparison

For the Biotechnology subindustry, vTv Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Moat Score falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
vTv Therapeutics (FRA:5VT0) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, vTv Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is vTv Therapeutics' Moat Score too high?
vTv Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. vTv Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, vTv Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Moat Score compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #587 out of 1400 companies for Moat Score. This puts vTv Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. vTv Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Moat Score of 2. The stock's GF Value™ is €6,488.10, compared to a current price of €31.20 — trading 99.5% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €31.20 is trading 99.5% below its estimated GF Value™ of €6,488.10.

Key valuation signals for FRA:5VT0:

  • Moat Score: 2
  • GF Value™: €6,488.10 vs. price of €31.20 (99.5% below fair value)
  • GF Score™: 35/100 with 1 warning sign
  • Industry Position: 0% at the Biotechnology median (#587 of 1400)

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.20
Price
€6,488.10
GF Value